The impact of ruxolitinib treatment on inflammation‐mediated comorbidities in myelofibrosis and related neoplasms

Clinical Case Reports

Mads Emil Bjørn¹ 

[1] Department of Hematology, Roskilde University Hospital, Roskilde, Denmark

关键词: Autoimmunity;    comorbidities;    inflammation;    myelofibrosis;    myeloproliferative neoplasm;    remission;    ruxolitinib;   

DOI  :  10.1002/ccr3.281

来源: Wiley

【 摘 要 】

Key clinical message

The inflammation-mediated comorbidities in myelofibrosis (MF) and related neoplasms (MPNs) likely reflect the concurrent immune deregulation and systemic inflammatory nature of the MPNs, emphasizing the link between chronic systemic inflammation, immune deregulation, and the malignant clone. JAK1-2 inhibitors in MF-patients reduce constitutional symptoms and splenomegaly, but also taget autoimmune and inflammation-mediated comorbidities.

【 授权许可】

CC BY-NC   
© 2015 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.